胃肠间质瘤相关研究的计量分析
|
摘要
目的预测未来胃肠间质瘤(GIST)领域的研究热点及趋势。方法检索Web of Science数据库在2008～2017年所收录的胃肠间质瘤相关的所有SCI论文,通过对引文中平年每年发表论文数量,论文页数,引用文献数,被引次数,参与胃肠间质瘤研究的国家数量,发表胃肠间质瘤相关论文量排名前20的杂志期刊,累计出现数量排名前32的关键词进行综合分析。结果总共有10,440篇GIST相关引文被检索到。胃肠间质瘤相关论文的累计发表量符合线性关系。发表论文量前2名的杂志占所有已发表论文的总量的5. 88%。关键词出现频率的变化揭示了该领域研究热点的变化。结论 DOG1(Discovered on GIST-1),单克隆抗体及免疫治疗势必成为未来GIST研究的热点。
Objective To find out the future research hotspot and trends of gastrointestinal stromal tumors( GISTs) research. Methods Data were based on the Science Citation Index Expanded( SCIE),from the Institute of Scientific Information Web of Science database. Articles referring to GISTs during2008-2017 were concentrated on the analysis of the number of papers published,number of pages of papers,number of citations,number of citations,the number of countries involved in the study of gastrointestinal stromal tumor,the number of journals and periodicals ranked among the top 20 in terms of the number of papers related to gastrointestinal stromal tumor,and the number of keywords in the top 32 in terms of the accumulated number. Results This searching strategy located 10,440 publications on GISTs in the SCI database. The cumulative number of publication followed linear distribution( R~2= 0. 9994). The three most prolific journals are Journal of Clinical Oncology and Annals of Oncology,responsible for 5. 88 % of the publication. The change trends of author keywords may reveal the changes of research spots. Conclusion DOG1 and immunotherapy will undoubtedly maintain the hotspots of GISTs research in the next few decades.
Objective To find out the future research hotspot and trends of gastrointestinal stromal tumors( GISTs) research. Methods Data were based on the Science Citation Index Expanded( SCIE),from the Institute of Scientific Information Web of Science database. Articles referring to GISTs during2008-2017 were concentrated on the analysis of the number of papers published,number of pages of papers,number of citations,number of citations,the number of countries involved in the study of gastrointestinal stromal tumor,the number of journals and periodicals ranked among the top 20 in terms of the number of papers related to gastrointestinal stromal tumor,and the number of keywords in the top 32 in terms of the accumulated number. Results This searching strategy located 10,440 publications on GISTs in the SCI database. The cumulative number of publication followed linear distribution( R~2= 0. 9994). The three most prolific journals are Journal of Clinical Oncology and Annals of Oncology,responsible for 5. 88 % of the publication. The change trends of author keywords may reveal the changes of research spots. Conclusion DOG1 and immunotherapy will undoubtedly maintain the hotspots of GISTs research in the next few decades.
引文
[1]Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohistochemical,and molecular genetic study of 1765 cases with long-term follow-up[J].Am J Surg Pathol,2005,29(1):52-68.
[2]Sepe PS,Moparty B,Pitman MB,et al.EUS-guided FNA for the diagnosis of GI stromal cell tumors:sensitivity and cytologic yield[J].Gastrointest Endosc,2009,70(2):254-261.
[3]Hostein I,Faur N,Primois C,et al.BRAF mutation status in gastrointestinal stromal tumors[J].Am J Clin Pathol,2010,133(1):141-148.
[4]Gill AJ,Chou A,Vilain R,et al.Immunohistochemistry for SDHB divides gastrointestinal stromal tumors(GISTs)into 2 distinct types[J].Am J Surg Pathol,2010,34(5):636-644.
[5]Hirota S,Isozaki K,Moriyama Y,et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-580.
[6]Espinosa I,Lee CH,Kim MK,et al.A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors[J].Am J Surg Pathol,2008,32(2):210-218.
[7]Patil DT,Rubin BP.Gastrointestinal stromal tumor:advances in diagnosis and management[J].Arch Pathol Lab Med,2011,135(10):1298-1310.
[8]Miettinen M,Lasota J.Gastrointestinal stromal tumors:review on morphology,molecular pathology,prognosis,and differential diagnosis[J].Arch Pathol Lab Med,2006,130(10):1466-1478.
[9]Demetri GD,Benjamin RS,Blanke CD,et al.NCCN Task Force report:management of patients with gastrointestinal stromal tumor(GIST)-update of the NCCN clinical practice guidelines[J].J Natl Compr Canc Netw,2007,5(Suppl 2):S1-S29,S30.
[10]Gold JS,Dematteo RP.Combined surgical and molecular therapy:the gastrointestinal stromal tumor model[J].Ann Surg,2006,244(2):176-184.
[11]沈琳,李健,秦叔逵,等.中国胃肠间质瘤诊断治疗共识(2013年版)[J].临床肿瘤学杂志,2013(11):1025-1032.
[12]Choi H.Response evaluation of gastrointestinal stromal tumors[J].Oncologist,2008,13(Suppl 2):4-7.
[13]Dematteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
[14]Miettinen M,Makhlouf H,Sobin LH,et al.Gastrointestinal stromal tumors of the jejunum and ileum:a clinicopathologic,immunohistochemical,and molecular genetic study of 906 cases before imatinib with long-term follow-up[J].Am J Surg Pathol,2006,30(4):477-489.
[15]Corless CL,Ballman KV,Antonescu CR,et al.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor:the ACOSOG Z9001 trial[J].JClin Oncol,2014,32(15):1563-1570.
[16]Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial[J].Lancet,2006,368(9544):1329-1338.
[17]Patrikidou A,Domont J,Chabaud S,et al.Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group[J].Eur J Cancer,2016,52(1):173-180.
[18]Sanford M,Scott LJ.Imatinib:as adjuvant therapy for gastrointestinal stromal tumour[J].Drugs,2010,70(15):1963-1972.
[2]Sepe PS,Moparty B,Pitman MB,et al.EUS-guided FNA for the diagnosis of GI stromal cell tumors:sensitivity and cytologic yield[J].Gastrointest Endosc,2009,70(2):254-261.
[3]Hostein I,Faur N,Primois C,et al.BRAF mutation status in gastrointestinal stromal tumors[J].Am J Clin Pathol,2010,133(1):141-148.
[4]Gill AJ,Chou A,Vilain R,et al.Immunohistochemistry for SDHB divides gastrointestinal stromal tumors(GISTs)into 2 distinct types[J].Am J Surg Pathol,2010,34(5):636-644.
[5]Hirota S,Isozaki K,Moriyama Y,et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-580.
[6]Espinosa I,Lee CH,Kim MK,et al.A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors[J].Am J Surg Pathol,2008,32(2):210-218.
[7]Patil DT,Rubin BP.Gastrointestinal stromal tumor:advances in diagnosis and management[J].Arch Pathol Lab Med,2011,135(10):1298-1310.
[8]Miettinen M,Lasota J.Gastrointestinal stromal tumors:review on morphology,molecular pathology,prognosis,and differential diagnosis[J].Arch Pathol Lab Med,2006,130(10):1466-1478.
[9]Demetri GD,Benjamin RS,Blanke CD,et al.NCCN Task Force report:management of patients with gastrointestinal stromal tumor(GIST)-update of the NCCN clinical practice guidelines[J].J Natl Compr Canc Netw,2007,5(Suppl 2):S1-S29,S30.
[10]Gold JS,Dematteo RP.Combined surgical and molecular therapy:the gastrointestinal stromal tumor model[J].Ann Surg,2006,244(2):176-184.
[11]沈琳,李健,秦叔逵,等.中国胃肠间质瘤诊断治疗共识(2013年版)[J].临床肿瘤学杂志,2013(11):1025-1032.
[12]Choi H.Response evaluation of gastrointestinal stromal tumors[J].Oncologist,2008,13(Suppl 2):4-7.
[13]Dematteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
[14]Miettinen M,Makhlouf H,Sobin LH,et al.Gastrointestinal stromal tumors of the jejunum and ileum:a clinicopathologic,immunohistochemical,and molecular genetic study of 906 cases before imatinib with long-term follow-up[J].Am J Surg Pathol,2006,30(4):477-489.
[15]Corless CL,Ballman KV,Antonescu CR,et al.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor:the ACOSOG Z9001 trial[J].JClin Oncol,2014,32(15):1563-1570.
[16]Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial[J].Lancet,2006,368(9544):1329-1338.
[17]Patrikidou A,Domont J,Chabaud S,et al.Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group[J].Eur J Cancer,2016,52(1):173-180.
[18]Sanford M,Scott LJ.Imatinib:as adjuvant therapy for gastrointestinal stromal tumour[J].Drugs,2010,70(15):1963-1972.